StepUp.One’s Post

Oxford’s Theolytics wins £2m Innovate UK grant for cancer therapies 🪙🥼 Theolytics, a biotech developing oncolytic viral therapies, has been awarded £2 million via Innovate UK’s Transforming Cancer Therapeutics competition to support clinical development of its lead candidate THEO-260. The funding adds to the £19 million raised earlier this year from an investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures and Oxford University Innovation. It will primarily support the company’s upcoming phase 1 multi-centre, first-in-human trial to evaluate safety and tolerability of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer and determine the recommended phase 2 dose. The trial is expected to begin in the coming months. Continue reading... https://lnkd.in/e2DsiZRF #millions #finance #investing #science #technology #innovation #oxonnews #oxonhour #businessnews #businessintelligence

ℹ️ Syncona Limited , a London-based investment firm, expands its cancer biotech portfolio with significant investments: 🔬 iOnctura: Syncona leads an 80 million euros series B financing round, contributing 30 million euros, securing a 23% stake. iOnctura focuses on roginolisib, an allosteric modulator of PI3Kδ, showing promise in rare eye cancer and advancing into trials for lung cancer and myelofibrosis. 🌟 Yellowstone : Syncona invests £16.5 million in series A funding for Yellowstone, a UK biotech targeting HLA class II in cancers. Founded on research from Oxford University, Yellowstone aims to develop bispecific TCR-based therapies initially for AML, with plans for other cancers. Exciting advancements in precision oncology with potential breakthroughs in cancer treatment pathways! #BiotechInvestment #CancerResearch #PrecisionMedicine #SeriesFunding #Syncona #iOnctura #Yellowstone #HealthcareInnovation 3.5

A breathtaking leap in T-cell therapy innovation! 💡🧬✨ Adaptimmune's recent licensing agreement with Galapagos marks a transformative moment for cancer treatment. The deal involves uza-cel, a groundbreaking therapy for ovarian cancer, now expanding into head and neck cancers—potentially transforming outcomes for patients with solid tumors. The robust collaboration involves a substantial financial commitment from Galapagos: 💷 $100 million upfront, additional milestones totaling up to $665 million, and future royalties. This lifeline not only empowers Adaptimmune's continued innovation but also propels their afami-cel towards launch for treating synovial sarcoma. Investors are rallying, with shares surging by 21% pre-market! 📈 Such a strategic alliance reinforces the power of partnership in navigating financial challenges and maximising therapeutic impact. Embracing Galapagos' decentralized manufacturing could revolutionize treatment efficacy and accessibility. As we await FDA decisions and further trial results, this partnership kindles hope for those fighting cancer. ✊🎗️ #Innovation #CancerTreatment #BiotechIndustry

AIM-HI congratulates March Biosciences, led by CEO & Co-Founder Sarah Hein, Ph.D., the First Prize Winner with Distinction of our 2023 AIM-HI Women's Venture Competition, for closing a $28.4 million oversubscribed Series A financing. March Bio is an emerging clinical-stage #biotech company committed to combating challenging cancers and other diseases. Funds will support Phase 2 development of March Bio’s lead CD5 CAR-T therapy, MB-105, for T-cell lymphoma and pipeline candidates. Read More: https://bit.ly/4f10obZ The AIM-HI Women’s Venture Competition is a first-of-its-kind program that provides funding, coaching, and networking opportunities to women-led oncology startups. The competition’s review committees provided assessments and recommendations for recognizing the Women’s Venture Competition winners based on scientific and clinical merits and business impact for #cancer patients. Support Our Mission: https://bit.ly/47VzZJE #AIMHIaccelerator #WomenEmpowerment #DriveCuresForward Sujuan Ba Dimitra Georganopoulou Rose Wang Matt Tremblay, Ph.D. National Foundation for Cancer Research (NFCR) OncoDaily

🔬 Ever wondered how working at an Innovation Space may enhance your ability to collaborate and fast-forward your next groundbreaking innovation?   Basel-based Engimmune Therapeutics and the Swiss innovation center CSEM, housed at the Switzerland Innovation Park Basel Area - Main Campus HQ, discuss in an interview how and why they started to work together to advance cancer treatment. Watch it below 👇 Engimmune Therapeutics, also part of BaseLaunch's portfolio, is a spin-off from ETH Zürich on a quest to revolutionize cancer treatment with soluble T cell receptors (TCR). CSEM, a landmark of Swiss technological innovation, is on a mission to bridge the gap between research and industry. The synergy between Engimmune’s TCR technology and CSEM’s microfluidic prowess has set the stage for a leap in cancer therapy development. By encapsulating individual TCR tests in microscopic droplets, cross-contamination is eliminated, ensuring precise and reliable results. This innovation dramatically accelerates the screening process, turning what used to take months into a matter of weeks, and significantly increasing the number of TCR candidates that can be de-risked in preparation for clinical trials. Read the full article right here: https://lnkd.in/eiGCKE3Y Rodrigo Vazquez-Lombardi | Felix K. #innovation #startups #collaboration #healthcare #lifescience

We are immensely excited to announce our official launch as a company, with $150M Series A financing. Clasp Therapeutics aims to expand the reach of immuno-oncology by creating novel precision medicines to help people with cancer live longer and healthier lives.   We are developing unique antibody-like T cell engagers that can be matched to an individual’s immune system and their specific tumor’s genetics. By targeting the truncal driver mutations that lie at the root of cancer growth, we hope to give every patient the opportunity to respond to treatment.   Clasp was born out of scientific advancements made by its founders at The Johns Hopkins University, including Bert Vogelstein and Drew Pardoll. The company is helmed by industry veteran Robert Ross. The financing was led by Catalio Capital Management, Third Rock Ventures and Novo Holdings, with participation from Cure Ventures, Vivo Capital, Alexandria Real Estate Equities, Inc., Blackbird BioVentures, BrightEdge - American Cancer Society , and Pictet Group.   The goal of our approach is to create a personalized, but off-the-shelf therapy, that enlists all types of a patient’s T cells to eradicate tumor cells with absolute specificity.   For more information on today’s launch announcement, please see our press release: https://lnkd.in/eCGwcbDv You can learn more about Clasp by visiting our website here: www.clasptx.com   #patients #cancer #immunooncology #TCellEngagers #oncology #precisionmedicine  

ImmunoBlue, a promising biotech company founded by researchers, Elizabeth (Lizie) Sweeney and Rohan Fernandes, recently secured a Phase I STTR Award from the National Cancer Institute (NCI). ImmunoBlue’s groundbreaking work builds on extensive research conducted in collaboration with GWU on GW licensed technology, "T cells targeted against multiple antigens for cancer treatment," co-invented by Sweeney and Fernandes. This innovative approach aims to enhance treatment efficacy by tailoring T cell therapies to the unique characteristics of each patient’s tumor. The Phase I STTR Award from the NCI will enable ImmunoBlue to further demonstrate the feasibility of their personalized T cell product, paving the way for future clinical applications. We congratulate ImmunoBlue for this significant achievement and are excited about the potential impact of their work on the future of cancer treatment. Read more about the proposal here: https://lnkd.in/e5ZhvB_z. #GWU #TCO #Innovation #Biotech #CancerResearch #PersonalizedMedicine #Startup #NCI #Glioblastoma

Talus Bio tacks on $11M to target hard-to-reach transcription factors https://lnkd.in/gJtpH3ap Seattle-based Talus Bioscience has raised $11.2 million in an early fundraising round , money that will go toward advancing the biotech’s portfolio of preclinical cancer programs and help build out the biotech’s drug discovery platform. California VC Two Bear Capital led the charge for the “seed+” round, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC and BoxOne Ventures. Talus Bio is targeting a challenging transcription factor linked to prostate cancer, plus brachyury-driven cancers. Brachyury is a transcription factor that regulates tumor development in chordoma—a rare bone tumor that forms in the spine or base of the skull. Transcription factors are genome-regulating proteins that can direct which genes are turned on or off. However, when the process goes awry, the proteins can drive certain disease processes, such as cancer, diabetes, inflammatory diseases, fibrosis and neurological conditions. Talus Bio’s new funds will also go toward expanding the… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

🎉 Exciting News! 🎉 We are thrilled to announce that GlycoTherapeutics and chiron have been awarded the prestigious MIT Zuid-Nederland R&D subsidy! This grant, amounting to €700000+, will propel our joint project aimed at revolutionizing cancer therapy research. Our project focuses on developing and validating the innovative µMass microplate, a groundbreaking technology that enhances the preclinical testing of anti-cancer therapies. By creating more realistic testing conditions, this technology promises to improve the reliability of preclinical results, ultimately accelerating the development of effective cancer treatments. With this support, we are poised to make significant strides in cancer research, reducing the time and cost involved in bringing new therapies to market. This project not only aligns with but also contributes to the broader mission of improving health and extending lives, as outlined in the Dutch Knowledge and Innovation Agenda (KIA) for Health and Care. Stay tuned for updates as we embark on this exciting journey towards better cancer treatments! Together, we can make a difference. #CancerResearch #BiotechInnovation #MITZuid #Healthcare #Oncology #GlycoTherapeutics #chiron #InnovationInScience #GrantAward #Biotechnology

🌟 Inspiring Insights from the Cancer Diagnostics Panel at the Oncology Venture, Innovation & Partnering Summit! 🌟 Insightful panel organized by Mara Aspinall on Cancer Diagnostics, Screening, and Early Detection and moderated by Tom Miller, Founder & Managing Partner at GreyBird Ventures, LLC. The panel featured industry leaders and investors: Lisa Alderson, CEO of Adela, Inc. Anthony Chang, PhD, Founder & CEO of BAMF Health Alan Hirzel, Life Science Director and Investor, Former CEO of Abcam Darshana Zaveri, Founder and Managing Partner at Catalyst Health Ventures 🔑 Key Takeaway: Harnessing Multi-omics for Precision Medicine: The integration of multi-omics technologies is revolutionizing cancer diagnostics, enabling earlier detection and more personalized patient care. At Predicta Biosciences, we are deeply aligned with this approach as we develop next-generation diagnostic assays to advance precision medicine. #CancerDiagnostics #MultiOmics #PrecisionMedicine  #Innovation